Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMMART-ACT in Advanced Solid Tumors
NCT06630325Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib and osimertinib in sarcoma, prostate cancer (PCa), breast cancer and 2 more (7 arms), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Proportion of Participants Who Receive an ACT Therapy Based on a SMMART-ACT Tumor Board Recommendation at 30 days. Started Jun 2025; status: terminated.
02
Drugs
abemaciclibosimertinib
03
Conditions
sarcomaprostate cancer (PCa)breast cancerovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06630325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630325.